MediGene AG

euro adhoc: MediGene AG
MediGene intends to raise EUR16 MM in a share capital increase (E)

---------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. ---------------------------------------------------------------------

Martinsried - San Diego, March 4, 2004. The German-American biotech company MediGene AG (Frankfurt, Prime Standard: MDG) has finalized a three-step corporate action to increase cash available by approx. 16 million EUR. The first step will be a share capital increase by 10 % through a private placement under participation of Techno Venture Management (TVM) without subscription rights for shareholders. Approx. 1.1 million new shares will be issued at the average market price of the past five trading days, that is 6.80 EUR per share. In a second capital increase of 10 %, MediGene will submit an offer to current shareholders for again approx. 1.1 million new shares at 6.80 EUR each. In addition, MediGene will offer convertible bonds at the amount of 1.5 million EUR, which can be subscribed to by shareholders for 1 EUR each.  The conversion price is 7.50 EUR per share. The convertible bonds bear 4 % interest annually during the 4 years to maturity. Conversion is possible after a period of 12 months. MediGene can ask for conversion under certain circumstances. Subscription period wil be March 6 - 19, 2004.

According company´s statements the capital increase measures will extend the financial scope for MediGene AG and increase the current amount of cash to about 40 million EUR.

Due to these measures, the number of MediGene shares will rise from 11,228,362 to 13,474,032. The capital increase measures will be carried out with authorized and conditional capital. No further shareholder´s resolution is needed.

Contact: MediGene AG Email: investor@medigene.com Fax: ++49 - 89 - 85 65- 2920 Julia Hofmann, Public Relations, Tel.:++49 - 89 - 85 65- 3324 Dr. Michael Nettersheim, Investor Relations, Tel.:++49-89-8565-2946

end of announcement            euro adhoc 04.03.2004
---------------------------------------------------------------------

Further inquiry note: Julia Hofmann Tel.: +49 (0)89 8565 3324 E-Mail: j.hofmann@medigene.com

Branche: Biotechnology
ISIN:      DE0005020903
WKN:        502090
Index:    CDAX, Prime All Share, Prime Standard, Technologie All Share
Börsen:  Frankfurter Wertpapierbörse / regulated dealing
              Niedersächsische Börse zu Hannover / free trade
              Berliner Wertpapierbörse / free trade
              Bayerische Börse / free trade
              Hamburger Wertpapierbörse / free trade
              Bremer Wertpapierbörse (BWB) / free trade
              Börse Düsseldorf / free trade
              Baden-Württembergische Wertpapierbörse / free trade



Weitere Meldungen: MediGene AG

Das könnte Sie auch interessieren: